Olmesartan Medoxomil E Idroclorotiazide Alter (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil E Idroclorotiazide Alter, is an angiotensin II receptor blocker (ARB) presented as a oral tablet for systemic use. It treats hypertension, often in combination with a thiazide diuretic, and is prescribed for adults requiring blood pressure control.

GNH USA supplies Olmesartan Medoxomil E Idroclorotiazide Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil/hydrochlorothiazide is indicated for conditions affecting the cardiovascular system, primarily hypertension. It helps lower elevated blood pressure and reduce associated cardiovascular risk. - Hypertension: Lowers systolic and diastolic blood pressure, helping to prevent stroke and heart attack. - Hypertension with fluid retention: Combines ARB‑mediated vasodilation with diuretic‑induced fluid loss to improve blood pressure control. - High‑risk cardiovascular patients: Contributes to overall risk reduction when used as part of a comprehensive antihypertensive regimen.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia or severe electrolyte imbalance - Angio‑edema involving face, lips or airway - Liver function abnormalities - Blood dyscrasias such as agranulocytosis

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters. - Renal function: Assess baseline creatinine and eGFR, adjust if impaired. - Electrolytes: Monitor serum potassium and sodium, especially when combined with other diuretics. - Pregnancy: Avoid use; potential risk to fetus. - Concomitant drugs: Review for interactions that affect potassium or renal function. - Elderly patients: Start at lower dose and monitor for orthostatic hypotension. - Store at ambient temperature: Keep below 25°C, in original packaging, protected from moisture.

Olmesartan medoxomil/hydrochlorothiazide may interact with several drug classes; careful review is recommended.

Major Interactions (Avoid): - Aliskiren combined with concurrent ACE inhibitor or ARB therapy. - Potassium‑rich supplements or potassium‑sparing diuretics leading to hyperkalemia. - NSAIDs that may reduce antihypertensive efficacy and impair renal function.

Moderate Interactions (Monitor Closely): - Lithium: May increase serum lithium levels. - Antidiabetic agents: May require dose adjustment due to enhanced glucose lowering. - Other antihypertensives: May cause additive blood pressure reduction. - Corticosteroids: May potentiate electrolyte disturbances. - Antimicrobials such as trimethoprim‑sulfamethoxazole affecting potassium balance.